Human prothrombin complex - Octapharma

Drug Profile

Human prothrombin complex - Octapharma

Alternative Names: 4 Factor Prothrombin Concentrate Complex - Octapharma; 4-Factor PCC - Octapharma; 4F PCC - Octapharma; Ocplex; Octaplex; Pronativ

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Biological factors; Blood coagulation factors; Proteins
  • Mechanism of Action Factor IX stimulants; Factor VII stimulants; Factor X stimulants; Protein C inhibitors; Prothrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Surgical blood loss
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 25 May 2017 Human prothrombin complex is still in preregistration phase for Surgical blood loss in USA (IV)
  • 01 May 2017 Octapharma initiates enrolment in a phase III trial for Surgical blood loss in USA and Spain (IV) (NCT02740335)
  • 14 Apr 2016 Octapharma plans a phase III trial for Surgical blood loss in USA (IV) (NCT02740335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top